Home

ABOUT

Editorial

PRESS RELEASES

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

SUBSCRIBE

Market Reports

FDA

Executives

Funding

Non Profits

Hospitals

Acquisitions

Health

Biotechnology News Magazine

HomeBiologics

Biologics

OSTEOAMP® SELECT Flowable Allograft Bone Graft Launches Reports Bioventus

Its versatile handling is designed to satisfy the need for a flowable allograft product with cohesive properties, making it an attractive option for minimally invasive surgery (MIS), expandable cages and 3D-printed cages.

Bioventus Updates Indications for Use of Their EXOGEN Ultrasound Bone Healing System

EXOGEN uses process and promote fracture healing. It has an 86% heal rate for fractures not healing on their own1 and provides 38% faster healing of indicated fresh fractures.

National Institute for Health and Clinical Excellence Maintains Previous Recommendation for EXOGEN® Ultrasound Bone Healing System

EXOGEN uses natural bone healing process and promote fracture healing. It also has an 86% heal rate for fractures not healing on their own and provides 38% faster healing of fresh fractures.

Bioventus to Co-Develop Next Generation Placental Tissue Product for Knee Osteoarthritis with MTF Biologics

“Development of new orthobiologics offerings for osteoarthritis is a core focus for Bioventus and we are pleased to begin collaborating with MTF Biologics on a solution for knee OA that will offer symptom relief and potentially delay progression of the disease,” said Tony Bihl, CEO, Bioventus.

OSTEOAMP SELECT Fibers Launched by Bioventus

3/27/19: OSTEOAMP SELECT Fibers, an innovative addition to its allograft line of OSTEOAMP bone graft substitutes for spine, foot & ankle, orthopaedic, and trauma surgeons.

Bioventus Enters Into Definitive Agreement to Divest BMP Development Program to Viscogliosi Brothers, LLC

Bioventus has entered into a definitive agreement to divest its next generation bone morphogenetic protein (BMP) development program to a new company formed by Viscogliosi Brothers, LLC (VB), a private equity investment firm focused on developing innovative...

Bioventus to Co-Develop Next Generation Bone Allograft with LifeLink

2/26/18: Bioventus, a global leader in orthobiologic solutions, has entered into an agreement with LifeLink Tissue Bank, a division of LifeLink Foundation, Inc. headquartered in Tampa, FL, to co-develop a next generation bone allograft solution for use in spine and trauma surgery. Terms of the agreement were not disclosed

Meta-Analysis Reveals LIPUS as Alternative to Surgery for Established Nonunion Fractures

Low-intensity pulsed ultrasound (LIPUS) treatment can be an effective alternative to surgery for nonunions, which are fractures that fail to heal. This according to a systematic review and meta-analysis of 13 published studies that describe nonunions treated...

NovaBone Announces Irrigation Resistant Products with Carriers that have Synergistic Effect in Bone Formation

  NovaBone Products, a leading biologics medical device company, announces the addition of NovaBone IRM and NovaBone IRM MacroPOR to its portfolio of biologically active bone graft substitutes. NovaBone IRM, and NovaBone IRM MacroPOR are the most advanced bioactive...

By using this website you agree to accept Medical Device News Magazine Privacy Policy